A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential

Virology

Volumn 239, Issue 1, 1997, Pages 132-149

  Elbel, M ^a   Carl, S ^a   Spaderna, S ^a   Iftner, T ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53; TRANSFORMING PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE PHASE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONDYLOMA; CONTROLLED STUDY; DELETION MUTANT; DNA SYNTHESIS; FRAMESHIFT MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; RETICULOCYTE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; WART VIRUS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; RODENTIA;

EID: 0031455732     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8860     Document Type: Article

References (86)

1. Ausubel F. A., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A. Current Protocols in Molecular Biology. 1990;Greene Publishing and Wiley-Interscience, New York.
2. Baker S. J., Markowitz S., Fearon E. R., Willson J. K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:1990;912-915.
3. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461-468.
4. Barbosa M. S., Vass W. C., Lowy D. R., Schiller J. T. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J. Virol. 65:1991;292-298.
5. Barr B. B., Benton E. C., McLaren K., Bunney M. H., Smith I. W., Blessing K., Hunter J. A. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet. 1:1989;124-129.
6. Bartel P. L., Chien C. T., Sternglanz R., Fields S. Cellular Interactions in Development: A Practical Approach. 1993;Oxford University Press, Oxford. p. 153-179.
7. Berkhout R. J., Tieben L. M., Smits H. L., Bavinck J. N., Vermeer B. J., ter Schegget J. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J. Clin. Microbiol. 33:1995;690-695.
8. Böhm S., Wilczynski S. P., Pfister H., Iftner T. The predominant mRNA class in HPV16-infected genital neoplasias does not encode the E6 or the E7 protein. Int. J. Cancer. 55:1993;791-798.
9. Cepko C. L., Roberts B. E., Mulligan R. C. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell. 37:1984;1055-1062.
10. Chen J. J., Reid C. E., Band V., Androphy E. J. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science. 269:1995;529-531.
11. Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 5:1990;1603-1610.
12. J. E. Coligan, A. D. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, 1994, Current Protocols in Immunology, W. Strober, Greene Publishing and Wiley-Interscience, New York.
13. Crook T., Morgenstern J. P., Crawford L., Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 8:1989;513-519.
14. Crook T., Tidy J. A., Vousden K. H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 67:1991;547-556.
15. Crook T., Fisher C., Masterson P. J., Vousden K. H. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene. 9:1994;1225-1230.
16. Dalal S., Gao Q., Androphy E. J., Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol. 70:1996;683-688.
17. Danos O., Engel L. W., Chen E. Y., Yaniv M., Howley P. M. Comparative analysis of the human type 1a and bovine type 1 papillomavirus genomes. J. Virol. 46:1983;557-566.
18. Davies R., Hicks R., Crook T., Morris J., Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 67:1993;2521-2528.
19. de Villiers E. M., Gissmann L., zur Hausen H. Molecular cloning of viral DNA from human genital warts. J. Virol. 40:1981;932-935.
20. de Villiers E. M. Heterogeneity of the human papillomavirus group. J. Virol. 63:1989;4898-4903.
21. Demers G. W., Espling E., Harry J. B., Etscheid B. G., Galloway D. A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol. 70:1996;6862-6869.
22. Durfee T., Becherer K., Chen P. L., Yeh S. H., Yang Y., Kilburn A. E., Lee W. H., Elledge S. J. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev. 7:1993;555-569.
23. Dyson N., Howley P. M., Münger K., Harlow E. The human papilloma virus 16-E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:1989;934-937.
24. el Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
25. M. Elbel, 1997.
26. Fields S., Song O. A novel genetic system to detect protein-protein interactions. Nature. 340:1989;245-246.
27. Foster S. A., Demers G. W., Etscheid B. G., Galloway D. A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:1994;5698-5705.
28. Gage J. R., Meyers C., Wettstein F. O. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64:1990;723-730.
29. Goffeau A., Barrell B. G., Bussey H., Davis R. W., Dujon B., Feldmann H., Galibert F., Hoheisel J. D., Jacq C., Johnston M., Louis E. J., Mewes H. W., Murakami Y., Philippsen P., Tettelin H., Oliver S. G. Life with 6000 genes. Science. 274:1996.
30. Halbert C. L., Demers G. W., Galloway D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:1991;473-478.
31. Halbert C. L., Demers G. W., Galloway D. A. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66:1992;2125-2134.
32. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
33. Harry J. B., Wettstein F. O. Transforming properties of the cottontail rabbit papillomavirus oncoproteins LE6 and SE6 and of the E8 protein. J. Virol. 70:1996;3355-3362.
34. Hawley-Nelson P., Vousden K. H., Hubbert N. L., Lowy D. R., Schiller J. T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:1989;3905-3910.
35. Heck D. V., Yee C. L., Howley P. M., Münger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA. 89:1992;4442-4446.
36. Hiraiwa A., Kiyono T., Segawa K., Utsumi K. R., Ohashi M., Ishibashi M. Comparative study on E6 and E7 genes of some cutaneous and genital papillomaviruses of human origin for their ability to transform 3Y1 cells. Virology. 192:1993;102-111.
37. Hoxtell E. O., Mandel J. S., Murray S. S., Schuman L. M., Goltz R. W. Incidence of skin carcinoma after renal transplantation. Arch. Dermatol. 113:1977;436-438.
38. Hudson J. B., Bedell M. A., McCance D. J., Laiminis L. A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol. 64:1990;519-526.
39. Huibregtse J. M., Scheffner M., Howley P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:1991;4129-4135.
40. Huibregtse J. M., Scheffner M., Howley P. M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell Biol. 13:1993a;775-784.
41. Huibregtse J. M., Scheffner M., Howley P. M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell Biol. 13:1993b;4918-4927.
42. Huibregtse J. M., Scheffner M. Mechanisms of tumor suppressor protein inactivation by the human papillomavirus E6 and E7 oncoproteins. Semin. Virol. 5:1994;357-367.
43. Iftner T., Bierfelder S., Csapo Z., Pfister H. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J. Virol. 62:1988;3655-3661.
44. Iftner T., Sagner G., Pfister H., Wettstein F. O. The E7 protein of human papillomavirus 8 is a nonphosphorylated protein of 17 kDa and can be generated by two different mechanisms. Virology. 179:1990;428-436.
45. Jansen Dürr P. How viral oncogenes make the cell cycle. Trends Genet. 12:1996;270-275.
46. Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 256:1992;827-830.
47. Kiyono T., Nagashima K., Ishibashi M. The primary structure of major viral RNA in a rat cell line transfected with type 47 human papillomavirus DNA and the transforming activity of its cDNA and E6 gene. Virology. 173:1989;551-565.
48. Kiyono T., Hiraiwa A., Ishibashi M. Differences in transforming activity and coded amino acid sequence among E6 genes of several papillomaviruses associated with epidermodysplasia verruciformis. Virology. 186:1992;628-639.
49. Kiyono T., Hiraiwa A., Ishii S., Takahashi T., Ishibashi M. Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin. J. Virol. 68:1994;4656-4661.
50. Ko L. J., Prives C. p53: Puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
51. Lechner M. S., Mack D. H., Finicle A. B., Crook T., Vousden K. H., Laimins L. A. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:1992;3045-3052.
52. Lechner M. S., Laimins L. A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68:1994;4262-4273.
53. Li X., Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70:1996;4509-4516.
54. Maki C. G., Huibregtse J. M., Howley P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56:1996;2649-2654.
55. Maniatis T., Sambrook J., Fritsch E. F. Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory, Cold Spring Harbor.
56. Mansur C. P., Marcus B., Dalal S., Androphy E. J. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene. 10:1995;457-465.
57. Miller J. H. Experiments in Molecular Genetics. 1972;Cold Spring Harbor Laboratory, Cold Spring Harbor.
58. Mizushima S., Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic. Acids. Res. 18:1990;5322.
59. Münger K., Phelps W. C., Bubb V., Howley P. M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:1989;4417-4421.
60. Nakagawa S., Watanabe S., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Mutational analysis of human papillomavirus type 16 E6 protein: Transforming function for human cells and degradation of p53 in vitro. Virology. 212:1995;535-542.
61. G. Orth, 1987, The Papovaviridae, N. P. SalzmanP. M. Howley, 199, 243, Plenum Press, New York.
62. Pfister H. Human papillomaviruses and skin cancer. Semin. Cancer Biol. 3:1992;263-271.
63. Pim D., Storey A., Thomas M., Massimi P., Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene. 9:1994;1869-1876.
64. Rous P., Beard J. W. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J. Exp. Med. 62:1935;523-548.
65. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.
66. Scheffner M., Takahashi T., Huibregtse J. M., Minna J. D., Howley P. M. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J. Virol. 66:1992;5100-5105.
67. M. Scheffner, 1997.
68. Schmitt A., Harry J. B., Rapp B., Wettstein F. O., Iftner T. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J. Virol. 68:1994;7051-7059.
69. Schwarz E., Freese U. K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 314:1985;111-114.
70. Sedman S. A., Hubbert N. L., Vass W. C., Lowy D. R., Schiller J. T. Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J. Virol. 66:1992;4201-4208.
71. Seedorf K., Krammer G., Dürst M., Suhai S., Rowekamp W. G. Human papillomavirus type 16 DNA sequence. Virology. 145:1985;181-185.
72. Shamanin V., zur Hausen H., Lavergne D., Proby C. M., Leigh I. M., Neumann C., Hamm H., Goos M., Haustein U. F., Jung E. G. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J. Natl. Cancer Inst. 88:1996;802-811.
73. Sherman F., Fink G. R., Hicks J. B. Methods in Yeast Genetics. 1986;Cold Spring Harbor Laboratory, Cold Spring Harbor.
74. Sherman L., Schlegel R. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J. Virol. 70:1996;3269-3279.
75. Slebos R. J. C., Kessis T. D., Chen A. W., Han S. M., Hedrick L., Cho K. R. Functional Consequences of Directed Mutations in Human Papillomavirus E6 Proteins: Abrogation of p53-Mediated Cell Cycle Arrest Correlates with p53 Binding and Degradation in Vitro. Virology. 208:1995;111-120.
76. Smotkin D., Wettstein F. O. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc. Natl. Acad. Sci. USA. 83:1986;4680-4684.
77. Soni R., Carmichael J. P., Murray J. A. Parameters affecting lithium acetate-mediated transformation of Saccharomyces cerevisiae and development of a rapid and simplified procedure. Curr. Genet. 24:1993;455-459.
78. Steger G., Pfister H. In vitro expressed HPV 8 E6 protein does not bind p53. Arch. Virol. 125:1992;355-360.
79. Tong X., Howley P. M. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc. Natl. Acad. Sci. USA. 94:1997;4412-4417.
80. von Knebel Doeberitz M., Oltersdorf T., Schwarz E., Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res. 48:1988;3780-3786.
81. von Knebel Doeberitz M., Rittmüller C., zur Hausen H., Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer. 51:1992;831-834.
82. Vousden K. H. Human Papillomavirus transforming genes. Semin. Virol. 2:1991;307-317.
83. Watanabe S., Kanda T., Yoshiike K. Human papillomavirus type 16 transformation of primary human embryonic fibroblasts requires expression of open rading frames E6 and E7. J. Virol. 63:1989;965-969.
84. Zakut Houri R., Bienz Tadmor B., Givol D., Oren M. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J. 4:1985;1251-1255.
85. Zeltner R., Borenstein L. A., Wettstein F. O., Iftner T. Changes in RNA expression pattern during the malignant progression of cottontail rabbit papillomavirus-induced tumors in rabbits. J. Virol. 68:1994;3620-3630.
86. H. zur Hausen, 1994, Human Pathogenic Papillomaviruses, H. zur Hausen, 131, 155, Springer Verlag.